Key result
NLRP3 deficiency exacerbated doxorubicin-induced cardiac dysfunction and injury independently of IL-1β, driven by decreased macrophage IL-10 production.
p-value: p=<0.01
NLRP3 deficiency exacerbates doxorubicin-induced cardiotoxicity by reducing macrophage IL-10 production, identifying a novel inflammasome-independent protective role for NLRP3.
No takes yet. Share an insight, caveat, or question.
Should not prompt NLRP3 inhibition during doxorubicin therapy; leaves open macrophage IL-10 augmentation as a cardioprotective target.
Kobayashi et al. (2016) studied Doxorubicin-induced cardiotoxicity. NLRP3 deficiency vs. Wild-type mice was evaluated on Cardiac dysfunction (percentage fractional shortening) and injury (plasma CPK, CK-MB, LDH) 5 days after doxorubicin treatment (p=<0.01). NLRP3 deficiency exacerbated doxorubicin-induced cardiac dysfunction and injury independently of IL-1β, driven by decreased macrophage IL-10 production.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: